By Fineline Cube 
Jiangsu Asieris Pharmaceuticals Co., Ltd. (SHA: 688176) announced that its APLD-2304 flexible cystoscope has obtained EU CE certification. Billed as the world’s first portable single-use blue-light flexible cystoscope with photodynamic diagnostic capability, the approval gives Asieris a first-mover position in drug-device combination diagnostics for bladder cancer as it expands into the European market.
Regulatory Milestone
| Element | Detail |
|---|---|
| Agency | European Union (EU) notified body |
| Approval Type | CE certification |
| Product | APLD-2304 portable single-use blue-light flexible cystoscope |
| Indication | Examination and imaging during urological diagnostic procedures |
| Date | 28 Aug 2026 |
| Next Steps | European commercialization of APLD-2304 and the paired Hexvix drug-device combination solution |
Product Profile & Innovation
- Device: APLD-2304 flexible cystoscope — portable, flexible, sterile, single-use design
- Technology: World’s first portable single-use cystoscope featuring blue-light photodynamic diagnostic capability
- Combination Solution: Paired with the blue-light imaging agent Hexvix to form a bladder cancer diagnostic drug-device combination
- Clinical Goal: Improve bladder cancer detection rates and reduce recurrence rates
- Physician & Patient Benefits: Enhanced physician convenience, improved patient comfort, and reduced risk of cross-infection versus reusable scopes
Competitive Positioning
| Differentiator | Significance |
|---|---|
| First-in-category | No competing portable single-use blue-light flexible cystoscope on the market |
| Drug-device combination | Bundles the device with Hexvix imaging agent, creating an integrated diagnostic workflow |
| Single-use design | Eliminates reprocessing burden and cross-infection risk — a growing priority in endoscopy |
| Blue-light imaging | Photodynamic detection enhances visualization of lesions missed under standard white-light cystoscopy |
By pairing a single-use delivery device with a blue-light imaging agent, Asieris moves beyond selling a standalone instrument toward an integrated diagnostic ecosystem. The single-use architecture directly addresses persistent concerns around reprocessing costs and cross-infection in flexible endoscopy, while photodynamic diagnosis targets the high recurrence burden that drives repeated surveillance procedures in bladder cancer care.
Market Impact & Outlook
- European Entry: EU CE certification opens the European urology market for Asieris, adding a major international footprint to the company’s portfolio beyond China
- Bladder Cancer Dynamics: Bladder cancer requires one of the most intensive long-term surveillance regimens of any malignancy, supporting recurring demand for cystoscopy-based diagnostics
- Combination Economics: The APLD-2304 + Hexvix pairing creates dual revenue streams per procedure and reinforces customer stickiness across the diagnostic workflow
- Strategic Validation: The milestone validates Asieris’s drug-device combination strategy and differentiates the company (SHA: 688176) from conventional endoscope manufacturers competing primarily on hardware
Forward‑Looking Statements – This brief contains forward-looking statements regarding commercialization, market adoption, and competitive positioning. Actual results may differ materially due to regulatory, commercial, and other risks. Not investment advice.-Fineline Info & Tech